235 related articles for article (PubMed ID: 32381950)
1. [Myasthenia Gravis and Myositis(PD-1 Myopathy)].
Suzuki S
Gan To Kagaku Ryoho; 2020 Feb; 47(2):219-223. PubMed ID: 32381950
[TBL] [Abstract][Full Text] [Related]
2. Inflammatory myopathy associated with PD-1 inhibitors.
Seki M; Uruha A; Ohnuki Y; Kamada S; Noda T; Onda A; Ohira M; Isami A; Hiramatsu S; Hibino M; Nakane S; Noda S; Yutani S; Hanazono A; Yaguchi H; Takao M; Shiina T; Katsuno M; Nakahara J; Matsubara S; Nishino I; Suzuki S
J Autoimmun; 2019 Jun; 100():105-113. PubMed ID: 30862448
[TBL] [Abstract][Full Text] [Related]
3. Pembrolizumab-related systemic myositis involving ocular and hindneck muscles resembling myasthenic gravis: a case report.
Kamo H; Hatano T; Kanai K; Aoki N; Kamiyama D; Yokoyama K; Takanashi M; Yamashita Y; Shimo Y; Hattori N
BMC Neurol; 2019 Aug; 19(1):184. PubMed ID: 31382909
[TBL] [Abstract][Full Text] [Related]
4. [A case of anti-titin antibody positive nivolumab-related necrotizing myopathy with myasthenia gravis].
Isami A; Uchiyama A; Shimaoka Y; Suzuki S; Kawachi I; Fujita N
Rinsho Shinkeigaku; 2019 Jul; 59(7):431-435. PubMed ID: 31243249
[TBL] [Abstract][Full Text] [Related]
5. PD-1 Inhibitor-associated Myopathies: Emerging Immune-mediated Myopathies.
Liewluck T; Kao JC; Mauermann ML
J Immunother; 2018 May; 41(4):208-211. PubMed ID: 29200081
[TBL] [Abstract][Full Text] [Related]
6. Neuromuscular adverse events associated with anti-PD-1 monoclonal antibodies: Systematic review.
Johansen A; Christensen SJ; Scheie D; Højgaard JLS; Kondziella D
Neurology; 2019 Apr; 92(14):663-674. PubMed ID: 30850443
[TBL] [Abstract][Full Text] [Related]
7. Emerging PD-1 and PD-1L inhibitors-associated myopathy with a characteristic histopathological pattern.
Matas-García A; Milisenda JC; Selva-O'Callaghan A; Prieto-González S; Padrosa J; Cabrera C; Reguart N; Castrejón N; Solé M; Ros J; Trallero-Araguas E; Antoniol MN; Vila-Pijoan G; Grau JM
Autoimmun Rev; 2020 Feb; 19(2):102455. PubMed ID: 31838162
[TBL] [Abstract][Full Text] [Related]
8. Myasthenia gravis with inflammatory myopathy without elevation of creatine kinase.
Kanbayashi T; Tanaka S; Hatanaka Y; Uchio N; Shimizu J; Sonoo M
Neuromuscul Disord; 2021 Jun; 31(6):570-573. PubMed ID: 34016494
[TBL] [Abstract][Full Text] [Related]
9. Myocarditis and myositis/myasthenia gravis overlap syndrome induced by immune checkpoint inhibitor followed by esophageal hiatal hernia: A case report and review of the literature.
Yin B; Xiao J; Wang X; Li X; Guan Y; Chen J; Han P; Li K; Wang J
Front Med (Lausanne); 2022; 9():950801. PubMed ID: 36457566
[TBL] [Abstract][Full Text] [Related]
10. Marked Respiratory Failure in an Ambulant Patient with Immune-mediated Necrotizing Myopathy and Anti-Kv1.4 and Anti-titin Antibodies.
Sugiyama A; Onishi Y; Ito K; Shibuya K; Nakamura K; Oda F; Nishino I; Suzuki S; Kuwabara S
Intern Med; 2021 Aug; 60(16):2671-2675. PubMed ID: 33642484
[TBL] [Abstract][Full Text] [Related]
11. Neuromuscular Complications of Programmed Cell Death-1 (PD-1) Inhibitors.
Kao JC; Brickshawana A; Liewluck T
Curr Neurol Neurosci Rep; 2018 Aug; 18(10):63. PubMed ID: 30078154
[TBL] [Abstract][Full Text] [Related]
12. Muscle involvement in myasthenia gravis: Expanding the clinical spectrum of Myasthenia-Myositis association from a large cohort of patients.
Garibaldi M; Fionda L; Vanoli F; Leonardi L; Loreti S; Bucci E; Di Pasquale A; Morino S; Vizzaccaro E; Merlonghi G; Ceccanti M; Lucchini M; Mirabella M; Andreetta F; Pennisi EM; Petrucci A; Salvetti M; Antonini G
Autoimmun Rev; 2020 Apr; 19(4):102498. PubMed ID: 32062029
[TBL] [Abstract][Full Text] [Related]
13. Myasthenia gravis and myopathy after nivolumab treatment for non-small cell lung carcinoma: A case report.
Kim JS; Nam TS; Kim J; Kho BG; Park CK; Oh IJ; Kim YC
Thorac Cancer; 2019 Oct; 10(10):2045-2049. PubMed ID: 31436031
[TBL] [Abstract][Full Text] [Related]
14. [A case of myasthenia gravis and myositis induced by pembrolizumab].
Noda T; Kageyama H; Miura M; Tamura T; Ito H
Rinsho Shinkeigaku; 2019 Aug; 59(8):502-508. PubMed ID: 31341124
[TBL] [Abstract][Full Text] [Related]
15. Myositis as a neuromuscular complication of immune checkpoint inhibitors.
Vermeulen L; Depuydt CE; Weckx P; Bechter O; Van Damme P; Thal DR; Claeys KG
Acta Neurol Belg; 2020 Apr; 120(2):355-364. PubMed ID: 31993961
[TBL] [Abstract][Full Text] [Related]
16. Nivolumab-related myasthenia gravis with myositis and myocarditis in Japan.
Suzuki S; Ishikawa N; Konoeda F; Seki N; Fukushima S; Takahashi K; Uhara H; Hasegawa Y; Inomata S; Otani Y; Yokota K; Hirose T; Tanaka R; Suzuki N; Matsui M
Neurology; 2017 Sep; 89(11):1127-1134. PubMed ID: 28821685
[TBL] [Abstract][Full Text] [Related]
17. Clinical characteristics, treatment and outcome of nivolumab-induced myasthenia gravis.
Wang C; Zeng H; Fang W; Song L
Invest New Drugs; 2023 Apr; 41(2):333-339. PubMed ID: 36988830
[TBL] [Abstract][Full Text] [Related]
18. [Immune checkpoint inhibitor-induced anti-striational antibodies in myasthenia gravis and myositis: a case report].
Sugiyama Y; Esa Y; Watanabe A; Kobayashi J; Suzuki S; Takahashi D
Rinsho Shinkeigaku; 2021 Sep; 61(9):630-634. PubMed ID: 34433744
[TBL] [Abstract][Full Text] [Related]
19. Inflammatory myopathy with myasthenia gravis: Thymoma association and polymyositis pathology.
Uchio N; Taira K; Ikenaga C; Kadoya M; Unuma A; Yoshida K; Nakatani-Enomoto S; Hatanaka Y; Sakurai Y; Shiio Y; Kaida K; Kubota A; Toda T; Shimizu J
Neurol Neuroimmunol Neuroinflamm; 2019 Mar; 6(2):e535. PubMed ID: 30697585
[TBL] [Abstract][Full Text] [Related]
20. Pembrolizumab-induced myasthenia gravis-like disorder, ocular myositis, and hepatitis: a case report.
Tian CY; Ou YH; Chang SL; Lin CM
J Med Case Rep; 2021 Apr; 15(1):244. PubMed ID: 33926558
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
